Articles On Prescient Therapeutics (ASX:PTX)

Title Source Codes Date
Prescient Therapeutics (ASX: PTX) advances PTX-100 to pivotal Phase 2 study

Highlights PTX-100 Phase 1b trial in r/r TCL has been completed with encouraging results. Phase 2 registration trial is under planning phase. PTX-100 has been granted US Orphan Drug designation by US FDA in all TCLs. PTX-100 of Pr...

Kalkine Media PTX 3 months ago
Prescient Therapeutics (ASX: PTX) receives R&D Tax Rebate of $2.4M

Highlights Prescient Therapeutics has received AU$2.4 million as R&D Tax Incentive rebate for FY23. R&D Tax Incentive is given under a government program providing firms cash refunds of up to 43.5% of eligible R&D expenses....

Kalkine Media PTX 4 months ago
Encouraging outcomes from Prescient Therapeutics’ (ASX: PTX) clinical-stage assets light up last quarter

Highlights PTX is advancing its diversified pipeline of cancer therapies, backed by a world-class research, clinical and commercial team. PTX-100 Phase 1b trial data is expected in December 2023. Pre-clinical data of CellPryme surpass...

Kalkine Media PTX 4 months ago
MoneyTalks: Prescient set for ‘big pay day’; Aerometrex to grab ‘blue ocean’ AI opportunity

‘Big pay day’ for Prescient Therapeutics, says Pitt Street Aerometrex to benefit from the seismic shifts of Artificial Intelligence   Pitt Street Research has sent us its thesis on biotech stock, Prescient Therapeutics (ASX:PTX), with a v...

Stockhead PTX 4 months ago
Prescient’s (ASX: PTX) abstract for PTX-100 features on ASH website

Highlights Prescient Therapeutics’ abstract for PTX-100 has been published on the American Society of Hematology (ASH) website PTX-100 Phase 1b study is ongoing with patients with refractory and relapsed TCL The trial results are anti...

Kalkine Media PTX 5 months ago
Cancer fighter Prescient navigates challenging conditions for biotech, reports strong Q1 FY24

  PTX-100 Phase 1b study nearing completion; data to be reported at major haematology conference in December CellPryme pre-clinical data continues to surpass current cell therapy approaches Business development meetings with international...

Stockhead PTX 5 months ago
Prescient Therapeutics to present latest cancer treatment breakthroughs at world-leading conference

Australian clinical stage oncology company Prescient Therapeutics (ASX: PTX) is set to present the exciting results from its latest cancer treatment study at the world’s largest hematology event. Prescient’s abstract for results of its phas...

smallcaps.wpenginepowered.com PTX 6 months ago
Prescient Therapeutics (ASX: PTX) to present Phase 1b cancer trial data at prestigious haematology conference

Highlights Abstract for the Phase 1b cancer trial results will be presented at the world’s largest haematology conference. The latest development is a validation to PTX work in T cell lymphomas, an area of unmet clinical need. The ASH...

Kalkine Media PTX 6 months ago
Prescient to announce Phase 1b cancer trial results at world’s largest haematology conference

Prescient Therapeutics (ASX:PTX) has announced that its abstract for the results of a Phase 1b study in T-cell lymphomas has been accepted for poster presentation at the American Society of Hematology annual meeting in December....

BiotechDispatch PTX 6 months ago
ASX cancer stocks guide: Here’s everything you need to know

According to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO defines cancer as a generic term for a large group of diseases that can affect any part of the body with malignant tumours and neoplasms. W...

Stockhead PTX 6 months ago
Prescient Therapeutics prepares for ‘pivotal’ year of PTX-100 development to treat T-cell lymphomas

Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has reported a solid end to financial year 2023 which it says has set the stage for a pivotal 12 months to come and beyond. Front and centre of the company’s strategy is comm...

smallcaps.wpenginepowered.com PTX 7 months ago
Prescient Therapeutics (ASX:PTX) – TechKnow Invest Roadshow, August 2023

  Steven Yatomi Clarke – CEO and Managing Director – Prescient Therapeutics (ASX:PTX) is a clinical-stage biotech company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

ShareCafe PTX 8 months ago
Dr Boreham’s Crucible: Arovella Therapeutics

Tim Boreham highlights the potential for cancer treatment biotech Arovella Therapeutics. By Tim Boreham ASX code: ((ALA)) Share price: 4.8 cents Shares on issue: 899,149,698 Market cap: $44 million Chief executive officer: Dr Michael Baker...

FNArena PTX 9 months ago
Orphan drug designation has a direct impact on drug pricing for these pharma players

Orphan diseases are those impacting less than 200,000 patients Orphan drug designation ensures an exclusivity period for pharma companies The average orphan drug in the US retails for US$7,000 per month   Rare or ‘Orphan’ diseases affect...

Stockhead PTX 10 months ago
Prescient Therapeutics to present OmniCAR and CellPryme abstracts at international gene therapy conference

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical stage oncology company Prescient Therapeutics (ASX: PTX) will present two of its abstracts at an annual conference of the International Society of Cell &...

SmallCaps PTX 11 months ago
Prescient Therapeutics (ASX:PTX) to showcase CellPryme and OmniCAR data at ISCT event in Paris

Highlights OmniCAR and CellPryme abstracts of Prescient have been accepted for showcasing at the annual meeting of the prestigious International Society of Cell & Gene Therapy (ISCT) The two abstracts would also be published in the...

Kalkine Media PTX 11 months ago
Prescient Therapeutics (ASX:PTX) announces US-based Dr Ellen Feigal as new inclusion to Board

Highlights Dr Ellen Feigal is serving on the Boards of NASDAQ-listed biotechnology companies Xencor Inc, and NextCure She has been included in Prescient Therapeutics' Board as a US-based independent, Non-Executive Director Dr Feigal h...

Kalkine Media PTX 11 months ago
Prescient Therapeutics (ASX:PTX) makes progress in March 2023 quarter

Highlights Prescient has informed about progress with regard to its PTX-100 therapy and cell therapu OmniCAR The Company has received "excellent" results from the clinical trial of PTX-100 therapy (T Cell Lymphoma) CellPryme being eva...

Kalkine Media PTX 11 months ago
CRITERION: The ASX cancer fighters with a sting in their treatment tails

Amid the bombed-out biotech sector, early-stage developers of a new cancer immunotherapy have caught the eye of investors after some promising clinical news. These companies are working on so-called CAR-T therapies, which work by ‘superchar...

Stockhead PTX 11 months ago
Health Kick Podcast: Prescient Therapeutics’ PTX-10 continues to show encouraging results following FDA Orphan Drug Designation 

Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast.  In this episode Tim chats to Steven Yatomi-Clarke, CEO of Prescient...

Stockhead PTX 1 year ago
Prescient Therapeutics hopes to accelerate bid for US FDA study approval for targeted therapy PTX-100

Prescient Therapeutics is hoping to follow in the footsteps of Neuren Pharmaceuticals after positive results from its latest Phase 1b clinical trial. Prescient Therapeutics (ASX:PTX) will seek approval from the US Food and Drug Administrat...

Stockhead PTX 1 year ago
Prescient Therapeutics’ PTX-100 continues showing promising results in clinical T cell lymphoma trial

This content is created by Smallcaps Authors. [Author : Filip Karinja] Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has announced continuing positive results in the PTX-100 phase 1b expansion cohort for relapsed and r...

SmallCaps PTX 1 year ago
ASX Health Stocks: High fives as Telix gets expanded FDA approval, Prescient’s PTX-100 returns good results

Telix Pharma gets FDA approval Prescient shows good data from Phase 1b clinical trial Incannex plans to open multiple psychedelic-assisted psychotherapy clinics in Australia and overseas   Telix Pharma (ASX:TLX) announced the US FDA has a...

Stockhead PTX 1 year ago
Prescient (ASX:PTX) reports promising clinical data for PTX-100 in relapsed and refractory TCL

Highlights Prescient Therapeutics (ASX:PTX) has updated on continued promising results in PTX-100 T Cell Lymphoma Phase 1b Cohort. The compound continues to exhibit an excellent safety profile, the company says. The latest data has ex...

Kalkine Media PTX 1 year ago
Big gains from tech and consumer discretionary boost ASX 0.05%

ShareCafeBig gains from tech and consumer discretionary boost ASX 0.05% by Peter Milios   Australian shares remained resilient to ex-dividend falls in major companies, including BHP (ASX:BHP), Rio Tinto (ASX:RIO), and CSL (ASX:CSL), as most...

ShareCafe PTX 1 year ago
CLOSING BELL: Corruption? In Africa? Over mining licences? That can’t be right, surely…

ASX 200 adds just 0.1% because it was literally the least it could do. Aussie tech stock surge negated by Doctors and Miners having a bad hair day. Two ASX-listed lithium players are under attack over alleged corruption in Africa, of all p...

Stockhead PTX 1 year ago
Prescient’s PTX-100 granted FDA’s Orphan Drug Designation for all T-cell lymphomas

The granting of an Orphan Drug Designation for PTX-100 gives Prescient guaranteed market exclusivity of 7 years. The US FDA has just granted Prescient Therapeutics (ASX:PTX)’s PTX-100 additional Orphan Drug Designation (ODD) for the treatme...

Stockhead PTX 1 year ago
Information Technology lifts ASX 0.1% at noon

ShareCafeInformation Technology lifts ASX 0.1% at noon by Peter Milios   Information Technology has boosted the S&P/ASX 200 0.1 per cent higher at 7311.3 at noon. The reason for this was the announcement from Xero (ASX:XRO), outlining t...

ShareCafe PTX 1 year ago
Prescient Therapeutics receives FDA orphan drug status for PTX-100 to treat T-cell lymphomas

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has secured an orphan drug designation from the US Food and Drug Administration (FDA) for its lead ca...

SmallCaps PTX 1 year ago
Stocks of the Hour: PTX, LIN, SLS

ShareCafeStocks of the Hour: PTX, LIN, SLS                    Prescient Therapeutics (ASX:PTX) has announced that the US FDA Grants Orphan Drug Designation to PTX-100 for broader TCL indications. Prescient Managing Director and CEO St...

ShareCafe PTX 1 year ago
FDA grants Prescient Therapeutics (ASX:PTX) broad orphan drug status for PTX-100 cancer treatment

US Food and Drug Administration (FDA) grants Prescient Therapeutics (PTX) broad orphan drug designation (ODD) for its PTX-100 drug The company had applied for ODD for the treatment of cutaneous T-cell lymphomas (CTCL), but the FDA grante...

themarketherald.com.au PTX 1 year ago
Stocks of the Hour: Prescient Therapeutics, Lindian Resources, Solstice Minerals

09 Mar 2023 - A snapshot of the stocks on the move featuring Prescient Therapeutics (ASX:PTX), Lindian Resources (ASX:LIN) and Solstice Minerals (ASX:SLS).

FNN PTX 1 year ago
Prescient Therapeutics (ASX:PTX) lands FDA Orphan Drug status for PTX-100, shares soar

Highlights Prescient Therapeutics’ PTX-100 therapy previously held Orphan Drug Designation (ODD) for peripheral TCL The US Food and Drug Administration has now granted PTX-100 ODD for all T-cell lymphomas including cutaneous TCL This...

Kalkine Media PTX 1 year ago
Guess which ASX biotech stock just rocketed 29% on big FDA news

A little-known ASX biotech stock is setting the bar high today. In morning trade on Thursday, the All Ordinaries Index (ASX: XAO) is up a slender 0.1%. But shares in this biotechnology company rocketed 29% in earlier trade. At the time of...

Motley Fool PTX 1 year ago
FDA grants 'orphan' designation to PTX-100 for broader TCL indications

Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced that the US FDA has granted Orphan Drug Designation for PTX-100 for the treatment of T-cell lymphomas, including cutaneous TCL.

BiotechDispatch PTX 1 year ago
Top 10 at 10: Gold, nickel finds and Orphan Drug Designation for a pharmaceutical player

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Stockhead PTX 1 year ago
Prescient Therapeutics (ASX:PTX) reports progress in cancer studies during H1 FY23

Highlights Prescient Therapeutics’ latest half-year report focuses on progress made on its targeted and cell therapies. The ASX-listed company, which is committed to developing novel cancer therapies, has also reported about new collabo...

Kalkine Media PTX 1 year ago
Prescient (ASX:PTX) ends last quarter on firm financial footing and key clinical developments

Highlights Prescient (ASX:PTX) highlights that its latest quarter achievements have strengthened its mark as an evolving player for the next generation of personalised therapies for cancer. During the quarter, PTX-100 showed promising...

Kalkine Media PTX 1 year ago
Major milestones Prescient Therapeutics (ASX:PTX) eyes in 2023

Highlights Prescient intends to modify the study protocol for enrolling additional CTCL patients for the clinical trial of PTX-100 Ongoing development of OmniCAR platform, towards clinical trials CellPryme-M can seamlessly integrate i...

Kalkine Media PTX 1 year ago
How this small-cap ASX biotech bolstered its cancer leadership position in 2022

Highlights Prescient marked a number of developments in 2022, cementing its lead in cancer therapy innovation. PTX-100, being studied in a type of rare blood cancer, continued to demonstrate encouraging clinical activity with a very fa...

Kalkine Media PTX 1 year ago
Inside Prescient Therapeutics’ (ASX:PTX) clinical progress to cancer treatment

Highlights: Prescient is developing a portfolio of targeted therapies and cell therapies for cancer treatment. In September, the company joined hands with MD Anderson Cancer Center. The company believes CellPryme is now ready for clin...

Kalkine Media PTX 1 year ago
Year in Review: Prescient Therapeutics (ASX:PTX) with CEO and managing director, Steven Yatomi-Clarke

Stockhead’s Year in Review video series is a yearly wrap up address from company leaders showcasing latest achievements, discoveries and developments of emerging ASX companies.  In this instalment Steven Yatomi-Clarke, CEO and managing dire...

Stockhead PTX 1 year ago
Prescient shows that PTX-100 is safe and effective on difficult to treat T-cell lymphomas

Prescient’s PTX-100 Phase 1b study shows encouraging responses on a patient population that is notoriously difficult to treat. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has revealed that its PTX-100 Phase 1b clinical...

Stockhead PTX 1 year ago
Prescient Therapeutics reports positive safety data from PTX-100 study on T-cell lymphoma patients

A study by Prescient Therapeutics (ASX: PTX) into the effects of lead drug PTX-100 on relapsed and refractory T-cell lymphomas (TCL) continues to show encouraging clinical activity in a difficult-to-treat patient population. The study compr...

SmallCaps PTX 1 year ago
Vida Ventures MD says it’s a rosy outlook for biotech investment in Australia in the long run

27 new biotech companies listed on the ASX the last two years Australian companies need access to US capital to grow The AusBiotech investment conference kicks off next week in WA   The Covid-19 pandemic put Australia’s biotechnology sect...

Stockhead PTX 1 year ago
Last Orders: A fireside chat about the ASX market news you might have missed today

As the end of the day approaches, and with the benchmark struggling like a tired dog to keep its head above water, it’s time for us all to take a knee and rest awhile in front of a crackling fireplace and reminisce with a loved one about al...

Stockhead PTX 1 year ago
Market Highlights: Monday on local markets, US Q3 earnings, and 5 ASX small caps to watch today

SPI Futures imply the ASX 200 will start the day 1% lower Wall St struggled on Friday despite/because of robust jobs data US Q3 earnings to kick off with a big bank focus Local shares are poised to open lower on Monday with the ASX 200 No...

Stockhead PTX 1 year ago
Closing Bell: ASX meanders to unsatisfying close

Aussie markets end Friday on a -0.80% disappointment US signals new cannabis laws, good news for Aussie producers Zelensky the hot tip to win a rare mid-war Nobel Peace Prize   The ASX has dribbled  it’s way towards Friday’s -0.80% close,...

Stockhead PTX 1 year ago
Prescient Therapeutics at forefront of overcoming challenges with game-changing CAR-T cell cancer therapies

CAR-T therapy is leading the race as the holy grail to cure cancer but like many medical therapies it is not without problems, which Prescient Therapeutics is working to overcome. Cancer is the second leading cause of death globally to hear...

Stockhead PTX 1 year ago
Biotechnology investing for the social good – making money and a difference

Biotechnology investing provides investors chance for capital growth and to do social good ticking ESG boxes Ausbiotech receives increasing enquiries about gifting, bequesting or investing in medical companies for social good  Presicent sa...

Stockhead PTX 1 year ago